Emeryville, CA-based Gritstone Oncology named Karin Jooss as its chief scientific officer. Jooss was previously Pfizer’s head of cancer immunotherapeutics and immunopharmacology. She joins Gritstone six months after the company launched with a $102 million commitment from Versant Ventures, the Column Group, and several other investors.
Author: Alex Lash
I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy.
View all posts by Alex Lash
